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Background. Although band ligation is now recommended for preven- 
tion of rebleeding from oesophageal varices in cirrhosis, sclerotherapy 
is still widely used. Patients submitted to chronic sclerotherapy under- 
go several endoscopies and experience a large number of serious 
complications. However: long-term outcome is poorly defined. 
Aims. To assess the clinical course and prognostic indicators of patients 
undergoing chronic sclerotherapy for prevention of variceal rebleeding 
as a basis for future evaluation of long-term band ligation outcome. 
Mathods. Prospective cohort study; prognostic analysis by the Cox pro 
portional hazards model. 
Results. A total of 218 consecutive cirrhotic patients 137 Child class 
A, 154 8, 27 C] were enrolled in the study Varices were obliterated 
in 139 [64%] patients in a mean of 5 (22.61 sessions and recurred 
in 58/139 (4 I. 7 %] within one year A total of 132 [60%] patients 
experienced 283 rebleeding episodes and 73 [33%] died. Bleeding 
from oesophageal ulcers was the most serious complication causing 
14% of all rebleeding episodes. Significant prognostic indicators of 
sclerotherapy outcome were: Child-Pugh class for variceal obliteration,. 
gastric varices and platelet count for recurrence of varices; failure to 
obliterate varices, variceal size and gastric varices for rebleeding; 
blood urea nitrogen and failure to obliterate varices for death. Pres- 
ence of gastric varices was the only prognostic indicator for death in 
the 79 patients not achieving variceal obliteration. A mean of IO en- 
doscopies and of 6 hospital admissions were needed per each patient 
with an estimated cost of LJS$ 7154 per patient during the first two 
years of therapy 
Conclusions. Sclerotherapy is a very demanding and costly treatment, 
1 and is associated with frequent and serious sideeffects. The probability 
Fiwa: of treatment failure is significantly higher in Child C patients with gastric 
Depertment of Medicine, Depedele “V. varices. Alternative treatments should be considered for these patients. 
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Introduction 
Sclerotherapy is still widely used for the prevention of variceal rebleeding 
even though it is now recommended that elastic band ligation is to be pre- 
ferred ’ ‘. Even if sclerotherapy reduces the risk of rebleeding from oe- 
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sophageal varices by approximately half 3 4, it does re- 
quires a large number of endoscopies to achieve and 
maintain variceal obliteration during the course of the 
disease. It is also associated with a marked incidence 
of side-effects 5 which are frequently so severe as to re- 
quire specific and urgent treatment. Therefore, patients 
treated with chronic sclerotherapy for the prevention of 
rebleeding, as already pointed out will undergo many 
endoscopies and, moreover, frequent hospital admis- 
sions to monitor the effects of therapy and to treat the 
complications. To optimise the efficiency of chronic 
sclerotherapy only those patients with the lowest prob- 
ability of treatment failure should be selected, choos- 
ing alternative techniques for patients in whom failure 
is more likely. However, although several prospective 
studies have assessed the post therapeutic course of pa- 
tients undergoing sclerotherapy 6 7, prognostic indica- 
tors of sclerotherapy failure are poorly defined. Fur- 
thermore, better knowledge of prognostic indicators of 
sclerotherapy outcome may serve for future evaluation 
of long-term ligation. 
Therefore, the aim of the present prospective cohort 
study of the clinical course in patients submitted to 
chronic sclerotherapy of oesophageal varices for the 
prevention of rebleeding from oesophageal vat-ices, was 
to assess the prognostic indicators of treatment failure. 
Methods 
Patients 
All cirrhotic patients (total 218, 136 males, 82 fe- 
males) with recent bleeding from oesophageal varices, 
consecutively submitted to sclerotherapy of oe- 
sophageal varices for the prevention of recurrent bleed- 
ing from oesophageal varices at our department from 
July 1985 to June 1996, were prospectively enrolled in 
the study (Table I). Diagnosis of cirrhosis was based on 
a previous liver biopsy or on compatible clinical, labo- 
ratory and imaging findings. The aetiology of cirrhosis 
was considered to be alcoholic when patients, or their 
relatives, admitted an alcohol consumption of 80 g/day 
for at least 5 years. Routine anti-HCV (hepatitis C 
virus) test was not available in our Department until 
1992, and was, therefore, performed only in some of 
the patients studied. Variceal size was defined accord- 
ing to the criteria of the Italian Liver Cirrhosis Project 
8. When present, gastric varices were classified accord- 
ing to Korula et al. 9 as junctional when varices ap- 
peared as a continuation of oesophageal varices along 
the lesser curvature of the stomach and fundal when 
they extended to the fundus, distal to the gastro-oe- 
sophageal junction, or were confined to the fundus, 
without apparent continuity with the oesophageal 
varices. 
At our Department, patients are submitted to scle- 
rotherapy for the prevention of recurrent variceal 
bleeding if they had previously presented variceal 
bleeding under &blocker treatment or if they have con- 
traindications or are intolerant to &blockers. These pa- 
tients represent 20-25% of the whole population of cir- 
rhotic patients presenting with upper digestive bleed- 
ing. Of the remaining, some 25% die during the hospi- 
talization and approximately 50% are treated by p- 
blockers. 
Sclerotherapy and endoscopic follow-up 
Sclerotherapy was started at emergency endoscopy or 
within 48 hours of the termination of bleeding. In- 
travariceal injections (l-2 ml) of 1.5% sodium-tetrade- 
cyl-sulphate up to a total of 8- 12 ml were performed at 
each session. Sclerotherapy sessions were repeated at 
7-10 day intervals until variceal obliteration. En- 
doscopy was repeated six months after obliteration of 
varices and yearly thereafter. Patients remained in hos- 
pital for 24 hours after each sclerotherapy session. 
Variceal recurrence was treated by a further course of 
sclerotherapy until obliteration. 
Clinical follow-up and outcomes of interest 
Patients were monitored every three months or when- 
ever required. At each check-up biochemical liver and 
renal function tests and blood cell count were recorded 
as well as the appearance or worsening of signs of liv- 
er decompensation. Continued alcohol intake was as- 
sessed by interviewing the patients and their relatives. 
The outcomes of interest for the prognostic assessment 
were defined as follows: 
l variceal obliteration: disappearance of oesophageal 
varices or visible vessels with obliterated lumen 
confirmed by failure to inject sclerosant within 
them; 
l failure to obliterate varices: variceal obliteration not 
achieved within six months of sclerotherapy; 
l recurrence of varices: reappearance of injectable 
varices after eradication; 
l recurrent bleeding: any episode of haematemesis or 
melena following inclusion in the study after the 
first sclerotherapy session; 
l death from any cause. 
Index bleeding and rebleeding episodes were treated 
by terlipressin (2 mg every 6 hours intravenously (iv) 
for 24 hours) or somatostatin (250 ug/h as a continu- 
ous 24-hour intravenous infusion after an initial bolus 
injection of 250 ug, which was repeated at g-hour in- 
tervals), emergency sclerotherapy, and balloon tam- 
ponade, according to a standard protocol routinely in 
use at our institution. Blood transfusions were given 
only when the blood haemoglobin concentration was 
<8 g/dl. 
783 
Prognostic factors of uariceal sclerotherapy 
The following side-effects of sclerotherapy were 
sought: thoracic pain, dysphagia, fever or pleural effu- 
sion requiring treatment, post-injection bleeding re- 
quiring prolongation of hospital stay or active treat- 
ment, bleeding from oesophageal ulcers, oesophageal 
perforation, mediastinitis. The search for side-effects 
was based on patient interview and physical examina- 
tion. When asymptomatic pleural effusion was sus- 
pected at physical examination, a chest X-ray was per- 
formed. Portal hypertensive gastropathy was defined 
as mild when the gastric mucosa showed a “mosaic” 
pattern (multiple erythematous areas outlined by a 
white reticular network) or a “scarlatina-like” pattern 
(a fine pink speckling) on endoscopy, whereas severe 
gastropathy was defined by the presence of cherry red 
spots 5. Portal vein flow was monitored by doppler ul- 
trasound (US) every six months to identify portal vein 
thrombosis. All patients were followed until June 1997 
or until death. 
Statistical analysis 
Patients characteristics at inclusion in the study were 
described as proportions or means, as appropriate. Dif- 
ferences between means were assessed by Student’s t 
test and differences observed on contingency tables 
were assessed by the X2 test. The mean number of en- 
doscopies per patient and per months of observation 
was calculated as follows: [Z(total endoscopies/num- 
Table 1. Clinical characteristics of patients. 
ClJJJcel c~~titics 
Male sex 
Age [mean f SD1 
Alcohol >80 mg/day 
HbsAg' 
Anti-HCV# 
Child-Pugh 
i 
C 
Ascites 
PSE 
HCC 
BUN mg/dl" 
Platelet x 1 OCO/mln 
Haemoglobin g/din 
>I previous bleed 
WlteJe 
T 
JJestit 
SRIW Me 
b&l61 ha3883 ff38J td#J tlh&lJ k-f&J 
136 86 50 40 43 82 54 51 85 
60.1*11 59.6ztlO 61.1zt11 567ztll 60.32itll 59.6*11 61klO 60.4*lR 60~11 
30 22 8 8 14 21 9 16 14 
17 11 6 4 7 10 7 6 11 
70/88 43% 27/33 1 S/24 24/3 1 42/53 28/35 23&!9 47/59 
ITi 100 28 9 & Ei EiY :i 101 27 
27 11 T-2 8 3 
;j 
5 10 17 
99 54 45 27 27 67 32 41 58 
21 12 9 4 8 13 8 12 9 
18 12 6 7 5 9 9 5 11 
49.2*23 49.3*20 49.1zt24 475i22 50.2&27 495rt23 48.8&23 55.5~27 46rt20 
107r54 1 O&t52 1 o&&7 lOI* 112zt51 106zt54 1 osr54 1001t51 111~56 
101&E 9.9*2 10.5*9 IO&2 9.7*2 9.7*2 1 O.ErtS 9.7*-l 1 9.8&2 
140 92 48 32 60 84 56 47 93 
Variceal size 
Small 
Medium 
Large 
Gr;;Fnarices 166 111 
Junctional 
s: :Fl 
575 
48 63 98 
: i 2 
69" 
53 113 
Fundal 17 9 1E;4 
16 
16 
PHG 28 21 7 10 11 19 9 11 17 
Portal vein thmmobosis 8 4 4 3 1 5 3 2 6 
p-blockers 63 45 18 20 25 43 20 19 44 
PSE: portal-qc&ernic enoephelopethy; HGG: hepato-&k&r cerCn@me; BUN: &I& lyee nicrosen; q mean ;t s&&rd deviation?; PHG: portal h~rtensive gas- 
tmpathy; xr&ne anti-HGV u’aterminaticm was svrtil&b a&r f !% and was pa-d in 88 p&&s. 
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ber of months of follow-up)]/number of patients. Cu- 
mulative proportions of patients free of each of the out- 
comes of interest were computed by the Kaplan and 
Meier method and the observed differences were as- 
sessed by the log-rank test lo. Prognostic indicators of 
each outcome were assessed by the Cox model for pro- 
portional hazards “. Candidate prognostic variables 
were selected from the clinical and endoscopic patient 
characteristics recorded at the inclusion in the study 
(Table I) for the prediction of failure to obliterate 
vat-ices, rebleeding and death and, at the time of 
variceal obliteration, for the prediction of recurrence of 
varices. The number of variables to include in each of 
the final models was reduced by univariate analysis 
and by clinical judgement taking also into account pre- 
viously reported significant prognostic indicators in 
cirrhosis ‘?-15, in order to include in the model approxi- 
mately 1 variable per 5-10 observed events 16. 
Results 
Patients and follow-up 
Clinical characteristics of the 218 patients included in 
the study are shown in Table I. Aetiology of cirrhosis 
was alcohol abuse in 30 patients, HBV infection in 17; 
it was possible to determine anti-HCV in only 88 pa- 
tients and 70 (79.5%) of them resulted positive to the 
test. This prevalence of HCV infection corresponds to 
the prevalence we are currently observing in the popu- 
lation of cirrhotic patients admitted to our Department. 
It is, therefore, conceivable that the aetiology of cir- 
rhosis in the 83 patients in whom anti-HCV was not 
determined, was, indeed, HCV infection, at least in the 
majority of them. Of the 30 patients who admitted al- 
cohol abuse over the past 5 years, none was actively 
consuming alcohol at the time of inclusion in the study, 
and none admitted further alcohol abuse, during fol- 
low-up. Only 78 out of 218 were admitted at the time 
of their first variceal bleeding whereas the mean (+ 
SD) of previous bleeding episodes was 1.9 (+ 1.6) in 
the remaining 140 patients. Overall, 162 patients un- 
derwent the first sclerotherapy session during active 
variceal bleeding. A total of 63 patients, admitted after 
failure of P-blockers for the prevention of rebleeding, 
received sclerotherapy associated with a non selective 
P-blocker. In these patients, compliance with the p- 
blocker treatment was assessed, during follow-up, by 
checking the heart rate reduction of 25% with respect 
to the resting heart rate before treatment. The other 77 
patients with previous bleeding who were not receiv- 
ing treatment for the prevention of recurrent bleeding 
had not been previously observed at our department. 
Possibly, they were not treated on account of con- 
traindications or intolerance to P-blockers identified in 
the peripheral hospitals in which they were admitted at 
the time of the first bleeding and where sclerotherapy 
was not available. The median follow-up was 14 
months (range 1 to 96; mean 22.4k21.6). No patient 
was lost to follow-up. A total of 2,143 endoscopies 
were needed, and the mean number of endoscopies per 
patient and per month was 1.02+- 1.13. 
Variceal obliteration 
Variceal obliteration was achieved in 139/2 18 patients 
(64%) in a mean (+ SD) of 5 (k2.6) sclerotherapy ses- 
sions in 2.4 (k2.0) months. The cumulative proportion 
of patients with obliterated varices after 6 months was 
69% (Fig. 1). 
The median follow-up in the 139 patients in whom 
variceal obliteration was achieved was markedly 
longer than in those in whom varices were not obliter- 
ated being: 24 (range 1 to 96; mean 28+-21) and 6 
months (range 1 to 96; mean 13*20), respectively. The 
median number of endoscopies was 8 (range 2 to 40) 
in patients whose varices were obliterated and 5 (range 
2 to 17) in those in whom obliteration was not 
achieved; however, the mean number of endoscopies 
per month of follow-up was significantly lower in pa- 
tients with successful variceal obliteration (0.68kO.67 
vs 1.6221.48, respectively; p<O.OOOOl). 
Eleven candidate prognostic variables of failure to 
obliterate varices were entered in the final Cox model: 
sex, age, Child-Pugh class, blood urea nitrogen 
(BUN), platelet count, haemoglobin, number of previ- 
ous variceal bleeding episodes, variceal size, gastric 
varices, portal vein thrombosis on ultrasounds (US) 
and combination therapy with P-blockers. Only the 
Child-Pugh class was significantly associated with the 
0.00 1, , , , , 
MOllthSO 3 6 9 12 
Patimtsatrislc: 
218 108 50 32 24 
Fig. 1. Percentage of patients without varica:al obliteration. Numbers 
betow abscissa denote the number of patiknts in each observation 
period. 
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Gastric varices - 
Absent = 0 
&l&cgna;= 1 
= 
Platelet 
>8uaof3 = 0 
sBouclo = 1 
NS 1.4 D.01 1.36” 2.3f <O.OMllf 
i!Ls 1.5” . f 
NS 1.5 0.03 NS NS 
Varicaal size 
Sm6il=l 
Medium = 2 
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Variceal oblkeration - 
Yes =O 
No = 1 
NS NS NS 
i:;F& gja 
0:&P 
NS NS 1.82 o.ou1 3.03 -d3.M101 
BUN: mq/dl 
risk of failure to obliterate varices (p=O.O06; Table II). 
The cumulative percentages of patients with obliterat- 
ed varices after six months were 83% in Child-Pugh 
class A, 69% in B, 51% in C (p=O.Ol; log-rank test; 
Fig. 2). 
Recurrence of varices 
Varices recurred at least once in 58 out of 139 patients 
(41.7%) within 1 year of obliteration (Fig. 3). A second 
course of sclerotherapy led to re-obliteration of varices 
in 5 l/58 patients (87.9%). A second recurrence follow- 
ing re-obliteration was observed in 11 patients and 
1 
more than 2 recurrences in 11. 
1.00 
Fii. 8. Pe 
petielxs b 
denote’ M 
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Candidate prognostic indicators of the first variceal re- 
currence were: sex, age, number of previous variceal 
bleeding episodes, Child-Pugh class, BUN, platelet 
count, haemoglobin, variceal size before sclerotherapy, 
gastric varices, portal hypertensive gastropathy, portal 
vein thrombosis on US, number of sclerotherapy ses- 
sions needed to achieve variceal obliteration and com- 
bination therapy with &blockers. Two variables were 
found to be significant independent predictors of 
variceal recurrence: gastric varices (hazard ratio 1.4, 
confidence interval (CI) 1.1 to 1.9, p=O.Ol) (Fig. 4) and 
platelet count s8OOOO/pL (hazard ratio 1.5, CI 1.04 to 
2.5, p=O.O3) (Table II). 
1.00 
0.75 
0.00 
Mimthao 20 40 60 
PatWMlth9k 
ogaatrkvalgp: il l 28 7 -: 15 3 0 0' 
Funks: 13 2 cl 0 
Flip. 1. Pemntage of patiants frae of vsricaal racurrence au23rcling to 
gastric varices in the 139 patianta who achieved varioeal obliteration. 
Numbers b&w &sr&sa daunts n%rnbar of patients still at risk in 
each abservatidn period. 
Rebleeding 
Overall 136 out of the 218 patients rebled during fol- 
low-up. Of these, 102 rebled before, and 34 after, 
variceal obliteration: causes of rebleeding are shown in 
Table III. Cumulative proportion of patients free of re- 
bleeding was 42% after 1 year and 32% after 2 years. 
The following variables were included in the final Cox 
model for the analysis of the prognostic indicators of 
rebleeding: sex, age, Child-Pugh class, portal vein 
thrombosis on US, variceal size, gastric varices, portal 
hypertensive gastropathy, number of sclerotherapy ses- 
sions needed to obliterate varices, variceal obliteration, 
BUN, platelet count, number of previous variceal 
bleeding episodes, haemoglobin, P-blocker therapy. In- 
dependent predictors of the risk of rebleeding were: 
variceal size (hazard ratio 1.9; CI 1.19 to 3.04; 
p=O.O07) and failure to obliterate varices (hazard ratio 
1.82; 95% CI 1.26 to 2.63; p=O.OOl) (Fig. 5, Table II). 
When removing the number of sclerotherapy sessions 
Ii&la III. Causes of rebieeding. 
0.w j4 
0 12 24 36 48 MOOtlIe 
Patie& at risk wtth varkes 
Oblilrrated: 139 51 30 18 12 s 
MtoMltwated:79 15 3 2 0 0 
F@. 5. Percentage of patients free of rablaedihg according to variceal 
obliteration. Numbers beiow abscissa denote;number of patients still 
at risk in each observation period. 
needed to obliterate varices and variceal obliteration 
from the model, only the Child-Pugh class was found 
to be a significant indicator of the risk of rebleeding 
(hazard ratio 1.33; 95% CI 1.03 to 1.74; p=O.O28). 
During the course of sclerotherapy, before variceal 
obliteration, 102 patients out of the whole series of 2 18 
bled. The proportion of patients free of bleeding before 
variceal obliteration (computed by censoring the ob- 
servation at the time of variceal obliteration) was 26% 
1 year after starting sclerotherapy. Variceal size (haz- 
ard ratio 1.77, CI 1.02 to 3.07; p=O.O4) and gastric 
varices (hazard ratio 1.36, CI 1.07 to 1.75; p=O.O13) 
(Fig. 6) were the only significant, independent predic- 
tors of rebleeding risk by the Cox model analysis in- 
cluding the same set of variables as for the overall 
analysis of the rebleeding risk indicators. 
After variceal obliteration, 48 out of 139 (34%) rebled: 
one- and two-year cumulative proportions of patients 
free of rebleeding after variceal obliteration were 72% 
and 62%, respectively (Fig. 5). A separate analysis in 
this subgroup of patients, including the same set of 
variables as for the whole population, showed that 
variceal size (hazard ratio 1.80, CI 1.03 to 3.10; 
Prognostic factors of variceal sclerotherapy 
+ 
0.25 
0.00 
0 12 24 48 80 Months 
Pmisnr et risk wnb vorims 
obltume 139 101 71 45 24 13 6 
notobll&ated 79 22 14 7 5 4 3 
Fii. 6. Percentage of patients free of rebleading before obliteration, 
according to presence and type of gastric varices. Numbers below 
abscissa denote number of patients still at risk in each observation 
period. I 
p=O.O4) and Child-Pugh class (hazard ratio 1.67; CI 
1.02 to 2.70; p=O.O4) were significant, independent 
predictors of the rebleeding risk (Table II). In the 79 
patients in whom variceal obliteration was not 
achieved within 6 months, only the presence of gastric 
varices was an independent predictor of rebleeding 
(hazard ratio 1 S; p=O.O07). 
Survival 
Overall, 73 out of 218 patients (33%) died. Causes of 
death are reported in Table IV. Cumulative proportion 
of surviving patients was 78% after 1 year and 72% af- 
ter 2 years. The following variables were included in 
the final Cox model for the analysis of prognostic in- 
dicators of death: sex, age, Child-Pugh class, portal 
vein thrombosis on US, variceal size, gastric varices, 
variceal obliteration, BUN, number of previous 
variceal bleeding episodes, haemoglobin, &blocker 
therapy. The analysis showed that only failure to oblit- 
erate varices (hazard ratio 3.03, CI 1.84 to 4.82; 
p<O.OOOl) (Fig. 7) and BUN (hazard ratio per each in- 
crement of 1 mg/dl of BUN: 1 .O 15, CI 1 .OlO to 1.024; 
p=O.OOl) were significant death risk indicators (Table 
Table IV. Causes of death. 
Varicaal bleeding 25 (34.2%) 
Liver failure 27 [36.9%) 
Hepatocellular carcinoma 8 (IN%1 
Sepsis 7 IS.5461 
Unrelated to liver disease 6 18.2%) 
Total 73 
II). When removing from the model the number of 
sclerotherapy sessions needed to obliterate varices and 
variceal obliteration, the Child-Pugh class (hazard ra- 
tio 1.55; 95% CI 1.00 to 2.45; p=O.O5) and BUN (haz- 
ard ratio for each increment of 1 mg/dl of BUN: 1 .O 13, 
CI 1.004 to 1.02 1; p=O.O02) were found to be a signif- 
icant indicator of the risk of rebleeding. 
A separate analysis, including the same set of variables, 
showed that BUN (p=O.O02, Table II) was the only in- 
dependent predictor of death risk after variceal obliter- 
ation in the 139 patients achieving this goal, and that 
gastric varices (p=O.OOl) did so among the 79 patients 
not achieving v&ceal obliteration (Table II) (Fig. 8). 
1.00 J 
0.75 - 
$ 
I Vefieas net oblitafstad 
ii 
0.50 - 
ap 
0.25 
o.oof , , , , , , 
0 12 24 98 48 60 t+iontbe 
Patiemtsiitti8kwtthvarice-s 
ObstmeM: 139 101 71 45 24 13 6 
notes 79 22 14 7 5 4 3 
Fig. 7. Percentage of patients surviving according to variceai obliter- 
ation. Numbers below abscissa denote number of patients still et risk 
in each observation period. 
1.00 - 
I 
0.75 - 
i? 
i 0.50 - 
I 
s 
0.25 
17 Ftmdus 
0.00 1 
I 
i 
0 11 2; d I 48 Bb MO&S 
Patlsnts St risk 
Nogaetrlovurlcise: 57 21 12 7 5 4 
Junctbnal: 7 3 2 0 0 0 
Futius: 15 0 0 0 0 0 
Fig. 0. Percentage of patients surviving, according to prasenca and 
type of gastric varices. Numbers below abscissa denote number of 
patients still at risk in each observation period. 
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Complications 
A total of 135 patients (62%) developed at least one 
oesophageal ulcer. The most serious complication was 
bleeding from these ulcers, which was the source of 
14% of the rebleeding episodes. No patient experi- 
enced symptomatic oesophageal stenosis requiring 
mechanical oesophageal dilatation. No other serious 
complications, such as mediastinitis or oesophageal 
perforation, occurred (Table V). 
bble Z Side affects. 
Thoracie pain 14 (6.4%) 
Dysphagia requiring oesophageal dilatation 0 
Fever or pleural effusion requiring treatment 5 i2.3461 
Bacterial peritwiitis 5 (2.3%1 
Post injection bleeding requiring treatment 11 (5461 
Oesophageel ulcers 135 (62%) 
;+I bleeding fmm variceal ulcer 15 (6.8461 
Oesophegaal perforation 
Mediastinitis : 
i 
Other clinically relevant events 
Portal hypertensive gastropathy was present in 28 pa- 
tients at inclusion in the study and developed during 
follow-up in 58 out of 139 (42%) patients achieving 
variceal obliteration and in 15 out of 79 (19%) failing 
to reach variceal obliteration (p=O.O006). It was the 
source of rebleeding in 14% of the entire series of pa- 
tients and in 20% of the 139 patients achieving variceal 
obliteration. 
Gastric varices were present in 52 out of 218 patients 
(24%) at inclusion in the study, junctional in 22 (10%) 
and fundal in 30 (14%). During follow-up, gastric 
varices disappeared in 20 (82%) of the 22 patients with 
junctional varices and in 20 (66%) of the 30 with fun- 
da1 vat-ices at inclusion, whereas new varices appeared 
at the oesophago-gastric junction in 9 out of the 166 
(7%) patients free of gastric varices when they started 
on sclerotherapy and in the fundus in 2/166 (1%). 
Portal vein thrombosis was present in 8 patients at in- 
clusion in the study and developed during follow-up in 
9 more patients [8 of the 139 with variceal obliteration 
and 1 of the 79 without (p=O.lO)]. 
Costs of sclerotherapy 
Overall, the mean number of endoscopies per each pa- 
tient was 9.826.2. The indication to endoscopy was 
sclerotherapy in 60% and follow-up assessment in 
40% of the procedures. According to Medical charges 
in USA 7 the cost of one endoscopy is US$ 260, US$ 
453 for one sclerotherapy session and US$566 for one 
day of hospitalization. Based on these figures, it can be 
estimated that the mean cost to treat a patient with scle- 
rotherapy for the prevention of rebleeding is about 
US$ 7,200+3,200 in a mean follow-up time of 
22.4k21.6 months. 
According to the costs of these procedures at our hos- 
pital (i.e., Lit. 250,000 for one endoscopy, Lit. 750,000 
for one sclerotherapy session and Lit. 600,000 for one 
day in hospital) the mean cost of one course of scle- 
rotherapy is Lit. 9,100,000~5,900,000. 
Discussion 
This large cohort study showed that sclerotherapy of 
oesophageal varices for the prevention of rebleeding, is 
a very demanding therapy which requires a large num- 
ber of endoscopies due to the need for endoscopic fol- 
low-up and repeated courses of sclerotherapy for the 
many patients with recurrence of varices. Moreover, 
complications are not rare and may require hospital ad- 
mission, in some cases in an intensive care unit. Clear- 
ly, this discouraging picture may not reduce the 
favourable effect of sclerotherapy shown in several 
RCTs and meta-analyses . 3 4 However, our study ex- 
plored the less well-known reality of the long-term 
outcome of sclerotherapy beyond the ideal situation of 
clinical trials, which usually do not assess the overall 
impact of a therapy in clinical practice. 
Although the clinical impact of this study is greatly re- 
duced by the rapid spreading of band ligation, which is 
now recommended, in several guidelines, as the best 
endoscopic therapy for the prevention of rebleeding in 
cirrhosis ’ 2, it might be useful as a basis for future re- 
assessment of the efficiency of band ligation when 
long-term outcome studies become available also for 
this therapeutic approach. For example, it is notewor- 
thy, in this respect, that several recently published 
RCTs 17-‘0, comparing band ligation with sclerotherapy, 
reported a higher recurrence rate of varices in patients 
undergoing band ligation. If this observation is con- 
firmed by other studies, it could reduce or even abolish 
the advantage of band ligation vs sclerotherapy, in the 
long term. 
Outcome of treatment in this consecutive cohort of pa- 
tients was rather poor: variceal obliteration was 
achieved in two thirds of the patients, more than half of 
the patients rebled during the first year and one third 
died. Of course, outcome depends mainly on the sever- 
ity of the liver disease. However, it is also conceivable 
that the overall outcome is affected by sclerotherapy 
due to ensuing complications, although this potential 
harm was not apparent in the clinical trials where se- 
lected patients were enrolled. 
Variceal obliteration was achieved in 64% of patients, 
a proportion similar to that reported in a RCT in which 
the same sclerosant was used as in the present study, as 
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well as a similar sclerotherapy technique 21. Failure to 
obliterate vat-ices was predicted only by the Child- 
Pugh class, with a higher risk in C-class patients, 
whereas variceal size, previously suggested as an im- 
portant predictor of sclerotherapy failure 22, was not 
confirmed. On the other hand, the prognostic role of 
the Child-Pugh class is in keeping with the known re- 
lationship between severity of liver dysfunction and 
portal hypertension . 23 As expected, the recurrence rate 
of varices, in the first year after eradication, was almost 
50%, the risk of rebleeding was very high before 
variceal obliteration and was almost halved after erad- 
ication of the varices. 
This study shed further light on the role of gastric 
varices during the course of sclerotherapy of oe- 
sophageal varices. Patients with gastric varices, either 
junctional or fundal, had a significantly higher risk of 
rebleeding before achieving obliteration of oe- 
sophageal varices and those with fundal varices also 
had a significantly higher risk of death, in this time 
frame. Similar findings were previously reported by 
Korula et al. 9 although they did not perform a separate 
analysis bearing in mind the obliteration of oe- 
sophageal varices, and we failed to confirm the prog- 
nostic value of gastric varices when the whole follow- 
up, including also the follow-up time after variceal 
obliteration, is taken into account. Furthermore, gas- 
tric varices disappeared during the course of scle- 
rotherapy in several patients, even when they were lo- 
cated in the fundus, and appearance of newly formed 
gastric varices was rare. It is also of interest that the 
presence of gastric varices was a significant prognos- 
tic indicator of the risk of early recurrence of oe- 
sophageal varices. 
Other important prognostic indicators emerging from 
this study are: platelet count, variceal size, Child-Pugh 
class and BUN, which are well-known prognostic in- 
dicators in cirrhosis ‘*-I4 and it is not surprising that 
they may also predict the outcome of patients under- 
going sclerotherapy of oesophageal varices. Based on 
the prognostic information provided by our study, it 
might be suggested that Child-Pugh A and B-class pa- 
tients, not presenting gastric varices, are the best can- 
didates to sclerotherapy. Child C patients have the 
lowest probability of successful obliteration of varices 
and those with gastric varices have the highest risk not 
only of rebleeding and death before variceal oblitera- 
tion but also of variceal recurrence. Therefore, these 
patients at higher risk of sclerotherapy failure should 
be first considered for alternative treatments. TIPS, 
particularly in candidates for liver transplantation, 
might be a perspective if P-blockers have failed and 
band ligation is not feasible. In those patients at high 
risk and not suitable for other therapies, a brief course 
of sclerotherapy should be attempted and when oblit- 
eration of varices is achieved, a closer endoscopic fol- 
low-up should be planned in those patients with gas- 
tric varices because of the higher risk of recurrence of 
oesophageal varices. 
Unfortunately we were only recently able to perform 
endosonography and, therefore, we could not assess 
whether the prognostic indicators that we found are in- 
dependent of the presence of large para-oesophageal 
varices, recently reported as predictors of both failure 
of sclerotherapy 24 and recurrence of oesophageal 
varices 25. This relationship should be assessed in fur- 
ther studies as well as whether all these prognostic in- 
dicators also apply to elastic band ligation, as recently 
reported for the presence of large para-oesophageal 
varices for the risk of recurrence of varices 26. 
The attempt to obliterate varices and to proceed with 
early treatment of recurrences, required an extremely 
large number of endoscopies: approximately one every 
three months, for successful sclerotherapy, and three 
every two months when sclerotherapy failed to obliter- 
ate varices. Nearly two thirds of the patients developed 
oesophageal ulcerations and these were the third most 
frequent cause of rebleeding (14%). Although it is still 
unclear as to whether it should be considered a com- 
plication of sclerotherapy 27, portal hypertensive gas- 
tropathy developed significantly more frequently in 
patients achieving variceal obliteration than in those in 
whom obliteration failed, and was the cause of anoth- 
er 14% of rebleeding episodes. Therefore, even if no 
other serious complications were observed in this se- 
ries of patients, it might be conceived that near 28% of 
rebleeding episodes are a consequence of sclerothera- 
py itself. Portal vein thrombosis was rarely observed, 
probably confirming the previously reported finding 
that sclerotherapy is not associated with an increased 
risk of portal vein thrombosis 28. 
The lack of other serious complications was probably 
due to the relatively non aggressive sclerotherapy that 
we used following an earlier observation that the com- 
plication rate of sclerotherapy by means of sodium 
tetradecyl-sulphate was related to the total amount of 
the drug injected in each sclerotherapy session 29. 
The mean cost of the sclerotherapy programme was 
US$ 7,200 for a mean follow-up of less than 2 years. 
The comparison with the costs of other treatments 
would require taking into account many other vari- 
ables, but this was beyond the scope of our study, and 
we limited the analysis of costs to endoscopy. The 
most important source of costs we did not account for 
concerns the treatment of rebleeding episodes. Howev- 
er, it would probably not appreciably affect a compar- 
ison with costs of B-blockers since the rebleeding rate 
with these two treatment approaches is comparable 30. 
In conclusion, this study shows that the outcome of pa- 
tients surviving a variceal bleeding episode is general- 
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ly poor even after sclerotherapy. Sclerotherapy is not 
an easy approach for patients and implies a strict en- 
doscopic follow-up, high rate of complications and 
considerable costs. The best candidates for sclerother- 
apy are patients with Child-Pugh class A or B disease, 
without gastric varices. Whether these prognostic indi- 
cators apply also to elastic band ligation should be as- 
sessed in future outcome studies in which this therapy 
is used. 
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